Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma

Conditions:   Metastic Renal Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Second-line Treatment Interventions:   Biological: SHR-1210;   Biological: CIK cells Sponsor:   Tianjin Medical University Cancer Institute and Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials